JPWO2020219774A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020219774A5
JPWO2020219774A5 JP2021563165A JP2021563165A JPWO2020219774A5 JP WO2020219774 A5 JPWO2020219774 A5 JP WO2020219774A5 JP 2021563165 A JP2021563165 A JP 2021563165A JP 2021563165 A JP2021563165 A JP 2021563165A JP WO2020219774 A5 JPWO2020219774 A5 JP WO2020219774A5
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
antigen
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021563165A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530442A (ja
JP2022530442A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029656 external-priority patent/WO2020219774A1/en
Publication of JP2022530442A publication Critical patent/JP2022530442A/ja
Publication of JPWO2020219774A5 publication Critical patent/JPWO2020219774A5/ja
Publication of JP2022530442A5 publication Critical patent/JP2022530442A5/ja
Withdrawn legal-status Critical Current

Links

Images

JP2021563165A 2019-04-24 2020-04-23 アントラサイクリン抗体薬物複合体およびその使用 Withdrawn JP2022530442A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962838267P 2019-04-24 2019-04-24
US62/838,267 2019-04-24
PCT/US2020/029656 WO2020219774A1 (en) 2019-04-24 2020-04-23 Anthracycline antibody-drug conjugates and uses thereof

Publications (3)

Publication Number Publication Date
JP2022530442A JP2022530442A (ja) 2022-06-29
JPWO2020219774A5 true JPWO2020219774A5 (https=) 2023-05-01
JP2022530442A5 JP2022530442A5 (https=) 2023-05-01

Family

ID=72940981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563165A Withdrawn JP2022530442A (ja) 2019-04-24 2020-04-23 アントラサイクリン抗体薬物複合体およびその使用

Country Status (4)

Country Link
US (1) US20220226493A1 (https=)
EP (1) EP3959242A4 (https=)
JP (1) JP2022530442A (https=)
WO (1) WO2020219774A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3079215A1 (en) 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+ cells
CN121555430A (zh) 2018-05-11 2026-02-24 比姆医疗股份有限公司 使用可编程碱基编辑器系统取代病原性氨基酸的方法
CN113330026A (zh) * 2018-10-23 2021-08-31 美真达治疗公司 Fc沉默的抗体药物缀合物(ADC)及其用途
CN120399078B (zh) * 2025-05-08 2026-03-06 上海天泽云泰生物医药股份有限公司 靶向cd117的纳米抗体及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
CA2531684C (en) * 2003-07-22 2014-03-11 Crucell Holland B.V. Binding molecules against sars-coronavirus and uses thereof
US8722587B2 (en) * 2008-04-09 2014-05-13 The Trustees Of The University Of Pennsylvania Single chain fragment variable antibody libraries and uses thereof
DK2356270T3 (da) * 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
AR086044A1 (es) * 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
CN107148429B (zh) * 2014-11-10 2021-12-03 豪夫迈·罗氏有限公司 抗-pdgf-b抗体和使用方法
HK1249534A1 (zh) * 2015-04-06 2018-11-02 哈佛大学校长及研究员协会 用於非清髓性预处理的组合物和方法
CA2997444A1 (en) * 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
BR112018074453A2 (pt) * 2016-05-27 2019-03-19 Abbvie Biotherapeutics Inc. proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
BR112018076306A2 (pt) * 2016-06-17 2019-03-26 Magenta Therapeutics, Inc. composições e métodos para a supressão de células cd117+
CA3079215A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+ cells
WO2019084053A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
WO2019084067A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODIES AND METHODS OF USE
CA3079897A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+ cells
WO2019234694A2 (en) * 2018-06-07 2019-12-12 Magenta Therapeutics, Inc. Therapeutic methods using antibody drug conjugates (adcs)
CN113330026A (zh) * 2018-10-23 2021-08-31 美真达治疗公司 Fc沉默的抗体药物缀合物(ADC)及其用途
JP2022512781A (ja) * 2018-10-30 2022-02-07 マジェンタ セラピューティクス インコーポレイテッド 同種造血幹細胞移植の方法
EP3958909A4 (en) * 2019-04-24 2024-01-10 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODY DRUG CONJUGATES AND USES THEREOF
EP3958899A4 (en) * 2019-04-24 2023-08-02 Magenta Therapeutics, Inc. ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND THEIR USES
CA3134319A1 (en) * 2019-04-24 2020-10-29 Rahul Palchaudhuri Anti-cd117 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP7650819B2 (ja) 抗－ｃｄ４５抗体薬物コンジュゲート及びその使用
US20260078148A1 (en) Amatoxin antibody-drug conjugates and uses thereof
JP7709376B2 (ja) Ｆｃサイレンス化抗体薬物コンジュゲート（ＡＤＣ）及びその使用
JP2022512778A (ja) 抗－ｃｄ４５抗体及びそのコンジュゲート
US20220175944A1 (en) Anti-cd117 antibody-drug conjugates and uses thereof
JPWO2020219959A5 (https=)
US20220177577A1 (en) Anti-cd117 antibody drug conjugates and uses thereof
KR20220091567A (ko) 항-cd45 항체 및 이의 컨쥬게이트
JP2022529726A5 (https=)
US20220226493A1 (en) Anthracycline antibody-drug conjugates and uses thereof
JP2022530443A5 (https=)
JP2025172753A (ja) 自己免疫疾患を治療するための方法および組成物
JP2022529727A5 (https=)
JPWO2020219775A5 (https=)
JPWO2021087368A5 (https=)
JPWO2020219778A5 (https=)
JPWO2020219774A5 (https=)